Monday, March 28, 2022

USFDA :

 

1) USFDA amends emergency use authorization for Sotrovimab due to Omicron BA.2 Subvariant

Source: https://medicaldialogues.in/news/industry/pharma/usfda-amends-emergency-use-authorization-for-sotrovimab-due-to-omicron-ba2-subvariant-90486?infinitescroll=1

2)  Novaris gets USFDA nod for Pulvicto to treat prostate cancer

Source:https://medicaldialogues.in/news/industry/pharma/novartis-gets-usfda-nod-for-pluvicto-to-treat-prostate-cancer-90478